

Use of 2-Ethoxy(4H)-3,1-benzoxazin-4-one as a Precursor for Synthesis of Quinazoline and Quinazolinone Starting Materials

Maher A El-Hashash, Sameh A Rizk, Fakhry A El-Bassiouny Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, Egypt.

Khalid M Darwish

Chemistry Department, Science Faculty, University of Garyounis, Benghazi, Libya Corresponding Author: khaliddarwish1962@yahoo.com, Tel. +201113049976

Abstract:

The interactions of 2-ethoxy(4*H*)-3,1-benzoxazin-4-one (**1**) with various nitrogen nucleophiles such as ammonium acetate, hydrazine hydrate, ethanolamine, *p*-phenylenediamine, *o*-phenylenediamine, *o*-tolidine, dapsone, 2-aminophenol, 4-aminophenol, 4-aminobenzoic acid and 2-aminonicotinic acid have been discussed. The reactions of 2-thoxy-(3*H*)-quinazolin-4-one with ethyl chloroformate, phosphorus pentasulfide, chloroacetyl chloride and phosphorus oxychloride have also been investigated. Similar reactions of 2-ethoxy-4-chloroquinazoline with hydrazine hydrate and thiosemicarbazide have been introduced. Aminolysis of the 2-ethoxy group in some of the thiadiazoloquinazolinone derivatives has been attempted. The interactions of these aminolized derivatives and the 3-aminoquinazolinone with chloroacetyl chloride have been studied. All of the synthesized derivatives have been used in a wide range as starting materials for the synthesis of novel quinazoline and/or quinazolinones which have biological activity. The structures of all these products, obtained by heterocyclic ring opening and ring closure, were inferred by the IR, MS, ¹H NMR spectral as well as elemental analyses.

Keywords: Aminothiadiazole, Benzoxazin-4-one, *N*-nucleophile, quinazoline, quinazolin-4-one, thiosemicarbazide.

1. Introduction

3,1-Benzoxazin-4-ones can be considered as semiacid anhydrides which undergo many of the reactions of true acid anhydrides, but at a slower rate. This special reactivity allows this class of compounds to be useful as antimicrobial (Mathew *et al* 2010), anti-platelet aggregation (Pritchard *et al* 2007), human leukocyte elastase inhibitors (Pei-Wen Hsieh *et al* 2005), receptor agonist active (Ward *et al* 2007), receptor antagonist active (Deswal *et al* 2006, ohno *et al* 2006, Kern *et al* 2007, Powell *et al* 2007, Bromidge *et al* 2009), pesticides (Shakil *et al* 2010), tissue culture protective and *in vivo* model of neurodegeneration (Wang *et al* 2010) and improve the umbilical vein endothelial cells (Dong *et al* 2010). On the other hand, in recent years, there has been an increasing interest in the chemistry of 4(3*H*)-quinazolinones because of their biological importance. Many of them show antifungal (Bartroli *et al* 1998), antibacterial (Shiba *et al* 1997), anticancer (Abdel-Hamid *et al* 1997), anti-inflammatory (Barker 1995), anticonvulsant (Bekhit *et al* 1998), immunotropic (Gursoy *et al* 1995), hypolipidemic (Nawrocka *et al* 1997), antitumor (Kurogi *et al* 1996), antiulcer (Hame *et al* 1996), analgesic (Terashima *et al* 1995),



antiproliferative activities (Raffa et al 1999) and inhibitory effects (Baek et al 1998) for thymidylate synthase and poly(ADP-ribose) polymerase (PARP) (Griffin et al 1998). The 4(3H)-quinazolinones can act as semicyclic amides or iminols, due to the tautomeric phenomenon they have. Their reactions in either form with alkyl or acyl halides are perhaps the most interesting due to the large number of heterocycles that are obtained either directly or through further transformations of the initially formed products. Also quinazolines are a big family of heterocyclic compounds, which have shown broad variety of biological activity profiles (Jhone 1982, Brown 1996), e. g. analgesic, narcotic, diuretic, antihypertensive, antimalarial, sedative, hypoglycaemic, antibiotic, antitumoral and many others. It has been found (Armarego 1967) that the biological activity strongly depends on the type and place of the substituents in their molecules. Out of the wide substitution patterns known, 4-aminoquinazolines are useful as fungicides (Nakagami et al 1982, Haley 1994) anti-inflammatory (Palanki et al 1999, Myers et al 1998) anticancer (Baker 1999) anti-microbial and anti-hypertensive agents (Nauta 1976, Mizogami et al 1986). Some 4-anilinoquinazolines have found to be potential and highly selective inhibitors of human immunoglobulin E (Berger et al 2001) and epidermal growth factor receptor tyrosine kinase (Bridges 2001) which regulates the cell growth and proliferation, so they work as potent antiallergic or anticancer agents, respectively. Among the broad synthetic pathways for aminoquinazoline preparation (Katritzky et al 1996 and 2000) the substitution of chlorine atom in 4-chloroquinazolines by amines is the shortest and cheapest one. On the other hand, it is well known that heterocycle-bearing N-glycosides play a significant role as inhibitors, e. g. the tetrazole-bearing N-glycosides used as SGLT2 inhibitors (Gao et al 2010) where their hypoglycemic activity is tested in vivo by mice oral glucose tolerance test (OGTT). In the current article we report the synthesis of 4-aminoquinazoline-bearing N-glycosides in a similar way with exception of the endocyclic 2 ° nitrogen atom attached to the glucose moiety.

2. Results and Discussion

In this paper we used the 2-ethoxy(4H)-3,1-benzoxazin-4-one (1) to synthesize novel quinazoline and quinazolinone derivatives having active functional groups which make their parent compounds important to be used as starting materials for novel derivatives. This advantage will be revealed by the functional group (or groups) residing on position 2 of the benzoxazinone ring, on positions 2 and 3 of the quinazolin-4-one ring and positions 2 and 4 of the quinazoline ring. Thus, the fusion of compound 1 with ammonium acetate gave the quinazolin-4-one 4 (Scheme 1).

Scheme 1: synthetic pathway for compound 2

The structure of compound 2 was inferred by its ^{1}H NMR spectrum that showed a singlet at δ 12.30 which is attributable for NH group.



Compound 1 reacted with hydrazine hydrate in boiling ethanol to give 3-aminoquinazolinone 3 (Scheme 2).

Scheme 2: synthetic pathway for compound 3

The structure of compound 3 was assigned by its 1 H NMR spectrum that showed a singlet at δ 2.00 which is attributable for amino group.

Compound 1 was interacted with 2-aminoethanol in boiling ethanol to afford compound 4 which on heating above its melting point (120-121 °C) yielded the desired product 4a (Scheme 3).

Scheme 3: Synthetic pathway for compounds 4 and 4a

The elemental analyses and spectroscopic data for **4** and **4a** were consistent with the assigned structures and isolation of **4** ruled out an abnormal nucleophilic addition to C-2 to form an amidine salt that subsequently dehydrates to give the desired product **4a** (Dong *et al* 2010).

Compound 1 was reacted with p-phenylenediamine in boiling ethanol affording compound 5 (Scheme 4).

Scheme 4: synthetic pathway for compound 5

The structure of **5** was confirmed by microanalytical and spectral analysis.

Compound **1** was reacted with *o*-phenylenediamine in warming ethanol affording compound **6** (Scheme 5). Heating compound **6** above its melting point afforded compound **6a** with traces of compound **6b**.

Scheme 5: synthetic pathway for compounds 6, 6a and 6b



The ¹H NMR spectrum of **6a** devoid any band for the carbonyl group whereas the ¹H NMR of **6b** devoid any band for the ethoxy group.

Compound 1 was reacted with o-tolidine in boiling ethanol to give compound 7 (Scheme 6).

Scheme 6: synthetic pathway for compound **7**

The structure of compound 7 was assigned by its mass spectrum and elemental analysis.

Compound 1 was reacted with dapsone in boiling ethanol to give compound 8 (Scheme 7).

Scheme 7: synthetic pathway for compound 8

The structure of compound 8 was assigned by its mass spectrum and elemental analysis.

Compound 1 was reacted with 2-aminophenol in boiling ethanol to give compound 9 (Scheme 8).

Scheme 8: synthetic pathway for compounds9

Compound 1 was reacted with 4-aminophenol in boiling ethanol to give compound 10 (Scheme 9).



Scheme 9: synthetic pathway for compounds 10

The structures of compounds 9 and 10 were confirmed by microanalytical and spectral analysis.

Compound 1 was reacted with 4-aminobenzoic acid in boiling ethanol to give compound 11 (Scheme 10).

Scheme 10: synthetic pathway for compounds 11

Compound 1 was reacted with 2-aminonicotinic acid in boiling ethanol to give compound 12 (Scheme 11).

Scheme 11: synthetic pathway for compounds 12

The structures of products 11 and 12 were inferred by microanalytical and spectral analysis. The IR spectra for 11 and 12 showed absorption bands in the range 1704-1705 attributable to v_{max} of C=O groups of acids.

Compound 2 was reacted with ethyl chloroformate in dry pyridine to give compound 13 (Scheme 12).

$$\begin{array}{c|c}
O & O & O & O \\
N & OEt & Pyridine/ $OC & OEt \\
\hline
\end{array}$
2

CICOOEt

Pyridine/ $OC & OEt$

13$$

Scheme 12: synthetic pathway for compounds 13

The IR spectrum devoid any band of NH but rather revealed an absorption band at 1762 attributable to v_{max} of C=O group of ester.

Compound 2 was reacted with phosphorus pentasulfide in dry xylene to give compound 14 (Scheme 13).



Scheme 13: synthetic pathway for compounds 14

The IR spectrum devoid any band of C=O in the carbonyl region but rather revealed an absorption band at 1319 attributable to ν_{max} of C=S group.

Compound 2 was reacted with phosphorus oxychloride in water bath to give compound 15 (Scheme 14).

Scheme 14: synthetic pathway for compounds 15

The IR spectrum devoid any band of C=O in the carbonyl region.

Compound 15 was reacted with hydrazine hydrate in boiling ethanol to give compound 16 (Scheme 15).

Scheme 15: synthetic pathway for compounds 16

The IR spectrum revealed an absorption band in the range 3250-3300 attributable to v_{max} of NH₂ group.

Compound 15 was heated with thiosemicarbazide in AcOH / fused NaOAc to give product 17 (Scheme 16).

Scheme 16: synthetic pathway for compounds 17

The IR spectrum revealed an absorption band at 1381 attributable to v_{max} of C=S group.



Compound 1 was heated with thiadiazole derivatives in boiling AcOH/fused NaOAc affording compounds 18a-c (Scheme 17).

Scheme 17: synthetic pathway for compounds **18a-c**

The structures of 18a-c were assigned by their mass spectra and elemental analysis.

Compounds 18a-c were fused with ammonium acetate or formamide to give products 19a-c (Scheme 18).

Scheme 18: synthetic pathway for compounds 19a-c

The ¹H NMR spectrum devoid any band of ethoxy group.

Compounds 19a-c were reacted with chloroacetyl chloride in pyridine to give products 20a-c (Scheme 19).

$$\begin{array}{c} O \\ N-N \\ N \\ N+1 \\ N+1 \\ N+1 \\ N+2 \\ N+1 \\ N+1$$

Scheme 19: synthetic pathway for compounds 20a-c

Compound 3 was reacted with chloroacetyl chloride in pyridine to give compound 21 (Scheme 20).

Scheme 20: synthetic pathway for compound 21

The ${}^{1}H$ NMR spectra for **20** and **21** always revealed singlets at δ 8.00 and 8.11 for the amidicNH.



Experimental

All melting points recorded are uncorrected. The IR spectra were recorded on a Pye Unicam SP1200 spectrophotometer using KBr wafer technique. The $^1\text{H-NMR}$ spectra were determined on a Varian FT-200, Brucker AC-200 MHz spectrophotometry experiment using TMS as an internal standard. Chemical shifts (δ) are expressed in ppm. The mass spectra were determined using MP model NS-5988 and Shimadzu single focusing mass spectrometer (70 eV).

The 2-ethoxy(4H) –3,1–benzoxazin–4–one **1** was prepared according to methods available in the literature (Krantz *et al* 1990) and was immediately used after preparation, prior to each synthesis to avoid moisture.

2- Ethoxy-4(3H)quinazolinone **2.** 2-ethoxy(4H)-3,1-benzoxazin-4-one (0.01 mol) and ammonium acetate (0.01 mol) were fused using an oil bath for 2 h. The mixture was poured into an ice / water mixture and stirred. The yellowish white precipitate that separated out was filtered, washed, dried, and then crystallized from ethanol to give off-white crystals of compound **2**. M.p. 155-156 °C; yield 85 %; Anal. for $C_{10}H_{10}N_2O_2$ (m.wt. 190); Found: C, 63.16; H, 5.26; N, 14.74; Calcd: C, 63.22; H, 5.18; N, 14.72; IR v (cm⁻¹) 1671 (C=O), 3229 (NH); MS: m/z (int. %) [M+H]+190 (58%); ¹H-NMR (DMSO-d₆) δ 1.19 (t, 3H; OCH₂CH₃, J = 7.4 Hz), 4.29 (q, 2H; OCH₂CH₃, J = 7.4 Hz), 7.31-8.17 (4d, 4H; ArH), 12.30 (br s, 1H, *NH*).

3-Amino-2-ethoxyquinazolin-4(3H)-one **3.** 2-ethoxy-4*H*-3,1- benzoxazin-4-one (0.01 mol) was heated under reflux with hydrazine hydrate (0.02 mol) in ethanol (20 mL) for 3 h. The mixture was cooled, filtered off and crystallized from ethanol as off-white needles; yield 68 %; m.p. 172-173 °C. Anal. for $C_{10}H_{11}N_3O_2$ (m.w. 205); Found: C, 58.59; H, 5.42; N, 20.56; Calcd: C, 58.53; H, 5.37; N, 20.49; IR ν (cm⁻¹) 1671 (C=O), 1528 (C=N); 3389 (NH); 3443 (CH); MS: m/z (int. %) [M+H]⁺ 205 (78.3); ¹H-NMR (DMSO-d₆) δ 1.14 (t, 3H; OCH₂CH₃), 4.33 (q, 2H; OCH₂CH₃), 7.29-8.19 (m, 4H; ArH), 2.0 (s, NH, amine).

Synthesis of Compounds 4 and 4a

A mixture of compound 1 and ethanolamine (0.01mol each) in boiling ethanol (30 mL) was refluxed for 3h. Concentration of the solvent left a white precipitate of compound 4 which was crystallized from ethanol to affording off-white crystals. Heating of 4 above its melting point yielded the corresponding product 4a.

2-Ethoxycarbonylamino(β-hydroxyethyl)benzamide **4.** Yellowish white crystals from ethanol; m.p. 120-121 °C; yield 80 %; Anal. for $C_{12}H_{16}N_2O_4$ (m.w. 252); Found: C, 57.21; H, 6.29; N, 11.13; Calcd: C, 57.14; H, 6.35; N, 11.11; IR ν (cm⁻¹) 1636 (C=O), 1737 (C=O), 3069 (CH), 3130 (NH), 3342 (OH); MS: m/z (int. %) [M+H]⁺ 252 (42.3).

2-Ethoxy-3-(2-hydroxyethyl)quinazolin-4-one 4a.

Light brown crystals; m.p. 108-109 °C; yield 75 %; Anal. for $C_{12}H_{14}N_2O_3$ (m.w. 234); Found: C, 61.05; H, 5.98; N, 12.03; Calcd: C, 61.54; H, 5.98; N, 11.97; IR v (cm⁻¹) 1660 (C=O), 3340 (OH). MS: m/z (int. %) [M+H]⁺ 234 (58.0), 236 (12.8), 190 (100), 192 (22.3); 174 (22.3), 176 (12.4); ¹H-NMR (DMSO-d₆) δ 1.19 (t, 3H; OCH₂CH₃, J = 7.4 Hz), 3.52 (m, 2H, 2'-H), 4.32 (q, 2H; OCH₂CH₃, J = 7.4Hz), 4.13 (m, 1H, 1'-H), 5.72 (s, br., OH), 7.41- 8.16 (4 d, 4H; ArH).

2-Ethoxy-3-(4-aminophenyl)quinazolin-4-one **5.** A mixture of compound **1** (0.01 mol) and *p*-phenylene diamine (0.01 mol) in boiling ethanol (30 mL) was refluxed for 3 h. Concentration of the solution gave a solid which was filtered, washed, dried and then crystallized from ethanol to give blue crystals of product **5**; m.p. 105-106 °C; yield 80 %. Anal. for $C_{16}H_{12}N_3O_2$ (m.w. 278); Found: C, 69.22; H, 4.16; N, 15.08; Calcd: C, 69.06; H, 4.32; N, 15.10; IR ν (cm⁻¹) 1635 (C=N), 1670 (C=O), 3225 (NH). MS: m/z (int. %) [M+H]⁺ 278 (55.0), 280 (18.2), 191 (100), 193 (31.7), 175 (32.1), 177 (0.8), 157 (4.7), 159 (0.6), 130 (52.4), 132



(0.3), 93 (0.9), 95 (0.1), 78 (0.2), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; OCH₂CH₃, J = 6.9 Hz), 4.35 (q, 2H; OCH₂CH₃, J = 6.9Hz), 5.12 (s, 2H, NH₂), 6.70-7.43 (m, 4H; Ph-H), 7.47-8.19 (m, 4H, quinazolone).

Reactions of Compound 1 with o-phenylene diamine:

A mixture of compound **1** and *o*-phenylenediamine (0.01 mol each) was slightly warmed in ethanol (30 mL) for 15 min. The precipitate that separated out was filtered, washed, dried and then crystallized from ethanol to give light blue crystals of product **6**. Heating product **6** above its melting point gave dark blue residue of unstable melting point. Crystallization of the residue, using different ratios of benzene/ethanol, enabled the products **6a** and **6b** to be isolated. The purity of products was checked by different melting points and TLC.

3-(2-aminophenyl)-2-ethoxyquinazolin-4(3H)-one **6.** M.p. 105-106 \mathbb{C} ; yield 80 %. Anal. for $C_{16}H_{12}N_3O_2$ (m.w. 278); Found: C, 69.22; H, 4.16; N, 15.08; Calcd: C, 69.06; H, 4.32; N, 15.10; IR ν (cm⁻¹) 1635 (C=N), 1670 (C=O), 3225 (NH). MS: m/z (int. %) [M+H]+278 (55.0), 280 (18.2), 191 (100), 193 (31.7), 175 (32.1), 177 (0.8), 157 (4.7), 159 (0.6), 130 (52.4), 132 (0.3), 93 (0.9), 95 (0.1), 78 (0.2), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; OCH₂CH₃, J = 6.9 Hz), 4.36 (q, 2H; OCH₂CH₃, J = 6.9 Hz), 5.24 (s, 2H, NH₂), 6.71-7.42 (m, 4H; Ph-H), 7.29-8.19 (m, 4H, quinazolinone).

2-Ethoxy benzimidazolo-[1,2-c] quinazoline **6a.** M.p. 191-192 °C; yield 85 %. Anal. for $C_{16}H_{13}N_3O$ (m.w. 263); Found: C, 73.02; H, 4.94; N, 15.98; Calcd: C, 73.00; H, 4.94; N,15.97; IR v (cm⁻¹) 1607 (C=N). MS: m/z (int. %) $[M+H]^+$ 263 (66.0), 265 (17.3), 187 (44.8), 189 (4.8), 175 (28.4), 177 (11.1), 157 (3.3), 159 (0.1), 130 (78.9), 132 (12.4), 78 (2.4), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; -OCH₂CH₃, J = 7.1 Hz), 4.31 (q, 2H; OCH₂CH₃, J = 7.1), 7.52-7.92 (m, 4H, benzimidazole), 7.62-8.55 (2m, 4H; quinazoline).

Benzimidazo[2,1-b]quinazolin-5(1H)-one **6b.** M.p. 202-203 °C; yield 23 %. Anal. for $C_{14}H_9N_3O$ (m.w. 235); Found: C, 71.56; H, 3.85; N, 17.91; Calcd: C, 71.49; H, 3.83; N, 17.87; IR v (cm⁻¹) 1607 (C=N). MS: m/z (int. %) [M+H]+235 (26.0), 237 (1.8); ¹H-NMR (DMSO-d₆) δ 7.52-7.92 (m, 4H, PhH), 7.62-8.55 (2m, 4H; quinazoline), 6.88 (br s, 1 H, NH).

2-Ethoxy-3-(3,3'-dimethyl-4-amino)biphenyl quinazolin-4-one **7.** A mixture of benzoxazinone **1** and 3,3'-dimethyl-4,4'-biphenyldiamine (0.01 mol each) in boiling butanol (30 mL) was heated under reflux for 6 h. The solvent was concentrated leaving a solid gum which was washed, filtered, dried and then recrystallized from ethanol giving product **7** as dark brown crystals; m.p. 121-122 \mathbb{C} ; yield 80 %; Anal. for $\mathbb{C}_{24}\mathbb{H}_{23}\mathbb{N}_{3}\mathbb{O}_{2}$ (m.w. 385); Found: $\mathbb{C}_{74.53}$; H, 5.63; N, 10.79; Calcd: $\mathbb{C}_{74.80}$; H, 5.97; N, 10.90; IR $\mathbb{V}_{10.90}$ (c=N), 1675 (C=O), 3250 (NH). MS: m/z (int. %) [M+H]⁺ 385 (72.0), 387 (34.2), 228 (13.3), 230 (1.2), 198 (12.7), 200 (0.1), 194 (16.1), 196 (0.4), 191 (100), 193 (24.8), 175 (53.3), 177 (8.7), 157 (7.1), 159 (1.4), 154 (1.2), 156 (0.2), 130 (46.3), 132 (0.1), 78 (0.3), 80 (0.1); ¹H-NMR (DMSO-d₆) $\mathbb{V}_{10.90}$ 1.22 (t, 3H; $\mathbb{V}_{10.90}$ -OCH₂CH₃, $\mathbb{V}_{10.90}$ = 6.9 Hz), 2.21- 2.29 (s, 6H; 2Ar*CH*₃), 4.40 (q, 2H; $\mathbb{V}_{10.90}$ -OCH₂CH₃, $\mathbb{V}_{10.90}$ = 6.9 Hz), 5.08 (2H, s, NH₂), 6.90-7.80 (m, 6H; biphenyl-H), 7.33-8.19 (m, 4H, quinazolinone).

3-[4-(4-aminobenzenesulfonyl)phenyl]-2-ethoxyquinazolin-4(3H)-one **8.** Benzoxazinone **1** (0.01 mol) was dissolved in 20 ml of ethanol and then dapsone (0.03 mol) was added to it. The mixture was refluxed for 4h and cooled. The separated solid **8** was crystallized from ethanol as colorless crystals; m.p. 144-146°C; yield 61%; Anal. For $C_{22}H_{19}N_3O_4S$ (m.w. 421); Found: C, 62.77; H, 4.53; N, 99. 86; Calcd: C, 62.71; H, 4.51; N, 99.77; IR v (cm⁻¹) 1162 (S=O), 1631 (C=N), 1764 (C=O), 3230 (NH). MS: m/z (int. %) [M+H]⁺ 421 (12.0); 119 (100); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; -OCH₂CH₃, J = 6.9 Hz), 4.47 (q, 2H; -OCH₂CH₃ J = 6.9 Hz), 5.08 (2H, s, NH_2), 7.30-8.20 (m, 4H, quinazolinone), 7.22-8.35 (m, 8H; Ar-H).

Synthesis of compounds 9 and 10



A mixture of compound 1 and o-hydroxyaniline or p-hydroxyaniline (0.01 mol each) in 40 mL of boiling ethanol was refluxed for 3 h. The obtained precipitate was heated in a round bottom flask (25 mL) in an oil bath at 160 $^{\circ}$ C for 30 minutes. After cooling the products were crystallized from the proper solvent to give the corresponding quinazolinones 9 and 10, respectively.

2-Ethoxy-3-(2-hydroxyphenyl)quinazolin-4-one **9.** Dark brown crystals from light petroleum (100-120 °C); m.p. 89-90 °C; yield 80 %; Anal. for $C_{16}H_{14}N_2O_3$ (m.w. 284); Found: C, 67.31; H, 4.73; N, 9.89; Calcd: C, 67.60; H, 4.93; N, 9.86; IR ν (cm⁻¹) 1669 (C=O), 2988 (OH); MS: m/z (int. %) [M+H]⁺ 284 (48.0), 286 (6.3), 191 (100), 193 (43.3), 175 (18.2), 177 (0.1), 157 (4.7), 159 (1.2), 130 (67.1), 132 (6.3); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; -OCH₂CH₃, J = 7.4 Hz), 4.36 (q, 2H; -OCH₂CH₃ J = 7.4 Hz), 5.55 (s, H; OH), 6.76 – 7.67 (m, 4H; Ph-H), 7.30 – 8.19 (m, 4H, quinazolinone).

2-*Ethoxy-3-*(4-hydroxyphenyl)quinazolin-4-one **10.** Dark brown crystals from benzene; m.p. 105-106 °C; yield 80 %; Anal. for $C_{16}H_{14}N_2O_3$ (m.w. 284); Found: C, 67.42; H, 4.70; N, 9.81; Calcd: C, 67.60; H, 4.93; N, 9.86; IR v (cm⁻¹) 1671(C=O), 2992 (OH); MS: m/z (int. %) [M+H]⁺ 284 (43.0), 286 (16.3), 191 (100), 193 (52.3), 175 (20.8), 177 (0.1), 157 (4.3), 159 (0.5), 130 (57.4), 132 (7.9); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; -OCH₂CH₃, J = 7.4 Hz), 4.35 (q, 2H; -OCH₂CH₃ J = 7.4 Hz), 5.35 (s, H; OH), 6.68-7.69 (m, 4H; Ph-H), 7.43–8.19 (m, 4H, quinazolinone).

4-[2-Ethoxy-4-quinazolon-3-yl]benzoic acid **11.** A mixture of compound **1** (0.01 mol) and *p*-aminobenzoic acid in boiling butanol (30 mL) was refluxed for 3 h. Concentration of the solution gave a solid which was washed, filtered, dried and then crystallized from ethanol affording derivatives **11** as light brown crystals of m.p. 151-152 °C; yield 80 %; Anal. for $C_{17}H_{14}N_2O_4$ (m. w. 310); Found: C, 65.44; H, 4.72; N, 9.00; Calcd: C, 65.80; H, 4.52; N, 9.03; IR v (cm⁻¹) 1675, 1705 (2xC=O), 3355 (chelated OH); MS: m/z (int. %) [M+H]⁺ 310 (63.0), 312 (28.2), 191 (100), 193 (27.8), 175 (34.3), 177 (0.6), 130 (59.3), 132 (0.2), 122 (1.8), 124 (0.2), 78 (0.1), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; OCH₂CH₃, J = 6.9Hz), 4.36 (q, 2H;OCH₂CH₃, J = 6.9 Hz), 7.40-8.00 (m, 4H; PhH), 7.43-8.19 (m, 4H, quinazolinone), 10.6 (1H, acid proton).

2-[2-Ethoxy-4-oxoquinazolin-384H)-yl]pyridine-3-caboxylic acid **12.** A mixture of benzoxazinone **1** (0.01 mol) and 2-aminonicotinic acid (0.01 mol) in boiling butanol (30 mL) was refluxed for 6 h. Concentrating the solution gave a solid which was washed, filtered, dried and then crystallized from ethanol affording the quinazolinone **12** as brown crystals; m.p. 298-300 °C; yield 80 %; Anal. for $C_{16}H_{13}N_3O_4$ (m.w. 311); Found: C, 61.58; H, 4.26; N, 13.20; Calcd: C, 61.74; H, 4.18; N, 13.50; IR v (cm⁻¹) 1669, 1704 (2xC=O), 3255 (chelated OH); MS: m/z (int. %) [M+H]⁺ 311 (36.0), 313 (19.5), 191 (100), 193 (28.6), 175 (61.8), 177 (7.6), 157 (5.2), 159 (1.1), 130 (58.2), 132 (0.6), 123 (0.7), 125 (0.2), 79 (0.7), 81 (0.1); ¹H-NMR (DMSOd6) v 1.22 (t, 3H; -OCH₂CH₃, v 1 = 6.9 Hz), 4.37 (q, 2H; -OCH₂CH₃ v 1 = 6.9 Hz), 7.44 - 8.20 (m, 4H; quinazolinone), 6.97, 7.87, 8.41 (m, 3H; H-4, H-5, H-6, pyridine moiety).

3-Ethoxycarbonyl-2-ethoxyquinazolin-4-one 13. Compound 2 (0.01 mol) was heated under refluxed with ethyl chloroformate (0.01 mol) in 50 mL of dry pyridine for 4h. The excess solvent was distilled off and the solution was left to cool and then poured onto ice with stirring to obtain a crude product, which was filtered off, thoroughly washed with cold water, dried and crystallized from benzene affording products 13 as white crystals; m.p. 177-178 \mathbb{C} ; yield 92 %. Anal. for $C_{13}H_{14}N_2O_4$ (m.w. 262); Found: C, 59.65; C, 59.65; C, 59.54; C

2-Ethoxy-4(3H)quinazolin-4-thione 14. A solution of compound 2 and P_2S_5 (0.03 mol each) in dry xylene (50 mL) was boiled for 6 h. The reaction mixture was filtered while hot and then concentrated. The product



separated on cooling was crystallized from ethanol to give the product **14**. Brown crystals of m.p. 137-138 °C; yield 65 %. Anal. for $C_{10}H_{10}N_2OS$ (m.w. 206); Found: C, 58.15; H, 4.81; N, 13.52; S, 15.53; Calcd: C, 58.25; H, 4.85; N, 13.59; S, 15,53; IR v (cm⁻¹) 1319 (C=S), 1597 (C=N), 3137 (NH); MS: m/z (int. %) [M+H]⁺ 206 (55.7); ¹H-NMR (DMSO-d₆) δ 1.19 (t, 3H, -OCH₂CH₃, J = 7.4 Hz), 4.39 (q, 2H; -OCH₂CH₃, J = 7.4 Hz), 7.29-7.67 (m, 4H, ArH), 12.3 (br s, 1H, *NH*).

4-Chloro-2-ethoxyquinazoline **15.** A solution of 2-ethoxy-4(3*H*)quinazolinone **1** (0.01 mol) in phosphorus oxychloride (20 mL) was heated on a water bath at 70 °C for 2 h. The reaction mixture was then cooled and diluted with ice/water and the resulting precipitate was collected by filtration and recrystallized from CHCl₃ chloroform giving product **15** as light brown crystals; m.p. 180-182 °C; yield 85 %. Anal. For C₁₀H₉N₂OCl (m.w. 208.5); Found: C, 57.45; H, 4.31; N, 13.42; Cl, 17.00; Calcd: C, 57.55; H, 4.30; N, 13.43; Cl, 17.02; IR ν (cm⁻¹) 1622 (C=N); MS: m/z (int. %) [M+H]⁺ 208.5 (57.9); ¹H-NMR (DMSO-d₆) δ 1.19 (t, 3H, OCH₂CH₃, J = 7.4 Hz), 4.19 (q, 2H; -OCH₂CH₃, J = 7.4 Hz), 7.49-8.86 (m, 4H, ArH).

2-Ethoxyquinazolin-4-ylhydrazine **16.** An emulsion of product **15** (0.01mol) and hydrazine hydrate (0.05 mol) in benzene (15 mL) was stirred for 2 h. The benzene-insoluble gum obtained was treated and washed with water, dried and crystallized from ethanol giving reddish brown crystals of product **16**. Yield 68 %; m. p. 156-158 °C. *Anal.* for $C_{10}H_{12}N_4O$ (M. wt. 204); Found: C, 58.86; H, 5.78; N, 27.45; Calcd: C, 58.82; H, 5.88; N, 27.45; IR v (cm⁻¹) 1620 (C=N), 3160(NH), 3250, 3300 (NH₂); MS: m/z [M+H]⁺ 204; ¹H-NMR (DMSO-d₆) δ 1.18 (t, 3H, CH₃ of ethoxy J = 7.4 Hz), 4.17 (q, 2H, CH₂ of ethoxy J = 7.4 Hz), 7.40 - 8.06 (m, 4H, ArH), 8.65 (br. s, 3H, N*H* and N*H*₂).

4-(2-Ethoxyquinazolin-4-yl)thiosemicarbazide 17. A mixture of the quinazoline 15 and thiosemicarbazide (0.01 mol each) was heated under reflux in acetic acid / fused sodium acetate (30 mL / 2 g) for 3 h. Pouring the solution onto ice/water left a white solid which was filtered, washed with water, dried and recrystallized from ethanol giving white crystals of compound 17; yield 74 %; m.p. 128 -130 ℃. *Anal.* for C₁₁H₁₃N₅OS (m.wt. 263); Found: C, 53.38; H, 5.19; N, 28.39; Calcd: C, 53.44; H, 5.26; N, 28.34; IR υ (cm⁻¹) 1381 (C=S), 1620 (C=N), 3418, 3250 (NH and NH₂). MS: m/z [M+H]⁺ 263 (77%). ¹H-NMR (DMSO-d₆) δ 1.20 (t, 3H; CH₃ of ethoxy J = 7.2 Hz), 4.15 (q, 2H; CH₂ of ethoxy J = 7.2), 7.44-8.06(4d, 4H, ArH), 8.41 - 9.34 (2 br. s, 4H, 2NH and NH₂).

Synthesis of Compounds 18a-c

A mixture of compound 1 (0.01 mol) and the aminothiadiazole derivatives 2-phenyl-5-aminothiadiazole, 2-cinnamyl-5-aminothiadiazole and 2-phthalimidomethyl-5-aminothiadiazole (0.01 mol) was heated under reflux in boiling acetic acid / fused sodium acetate (30 mL / 2 g) for 3 h. The solution was poured into an ice / water mixture, stirred and left to settle down affording a white solid. The resulting solid was filtered, washed, dried and finally recrystallized from the proper solvent affording the derivatives 18a-c.

5-[2-Ethoxy-quinazolone-3-yl]-2-phenylthiadiazole **18a.** Brown crystals from DMF; m.p. 172-173 °C; yield 85 %. Anal. for $C_{18}H_{14}N_4O_2$ S (m.w. 350); Found: C, 61.88; H, 4.04; N, 16.08; S, 9.17; Calcd: C, 61.71; H, 4.00; N, 16.00; S, 9.14. IR v (cm⁻¹) 1630 (C=N), 1669 (C=O). MS: m/z (int. %) [M+H]⁺ 350 (78.0), 352 (31.1), 191 (100), 193 (23.7), 157 (4.4), 159 (0.1), 175 (49.5), 177 (9.7), 162 (38.2), 164 (3.6), 130 (61.2), 132 (4.1), 103 (1.8), 105 (0.2), 78 (0.7), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.22 (t, 3H; OCH₂CH₃, J = 7.1 Hz), 4.40 (q, 2H; -OCH₂CH₃, J = 7.1 Hz), 7.41 - 7.94 (m, 5H, Ph-H), 7.44 - 8.20 (m, 4H, quinazolinone).

5-[2-Ethoxy-quinazolone-3-yl]-2-cinnamylthiadiazole **18b.** Brown crystals from DMF; m.p. 289-290 $^{\circ}$ C; yield 85 %. Anal. for $^{\circ}$ C₂₀H₁₆N₄O₂ S (m.w. 376); Found: C, 68.99; H, 4.72; N, 16.00; S, 9.03; Calcd:



C, 68.97; H, 4.60; N, 16.09; S, 9.20. IR v (cm⁻¹) 1633 (C=N), 1689 (C=O). MS: m/z (int. %) [M+H]⁺ 376 (72.0), 378 (14.9), 191 (100), 193 (17.5), 188 (14.2), 190 (3.1), 175 (48.2), 177 (12.7), 157 (5.7), 159 (0.2), 130 (67.1), 132 (1.8), 129 (0.8), 131 (0.2), 122 (1.3), 124 (0.1), 78 (0.6), 80 (0.1). ¹H-NMR (DMSO-d₆) δ 1.23 (t, 3H; -OCH₂CH₃, J = 7.1 Hz), 4.43 (q, 2H; -OCH₂CH₃, J = 7.1 Hz); 7.42- 8.20 (4d, 4H, quinazolinone), 7.35 - 7.45 (m, 5H, Ph-H), 7.20, 7.47 (2d, 2H, J = 15.8 Hz, olefinic-H).

5-[2-Ethoxyquinazolone-3-yl]-2-phthalamidomethylthiadiazole **18c.** Brown crystals from DMF; m.p. 303-304 °C; yield 85 %. Anal. for $C_{21}H_{15}N_5O_4S$ (m.w. 433); found: C, 58.72; H, 3.66; N, 16.31; S, 7.42; Calcd: C, 58.20; H, 3.46; N, 16.17; S, 7.39. IR v (cm⁻¹) 1631 (C=N), 1670, 1727, 1776 (3xC=O). MS: m/z (int. %) [M+H]⁺ 433 (58.0), 435 (22.8), 245 (36.4), 247 (3.4), 191 (100), 193 (56.1), 186 (78.0), 188 (12.7), 175 (30.1), 177 (8.1), 157 (3.2), 159 (0.1), 147 (8.3), 149 (0.3), 130 (48.3), 132 (6.4), 122 (4.5), 124 (0.2), 78 (0.3), 80 (0.1); ¹H-NMR (DMSO-d₆) δ 1.21 (t, 3H; -OCH₂CH₃, J = 7.1 Hz), 4.48 (q, 2H; -OCH₂CH₃, J = 7.1 Hz), 5.16 (s, 2H; CH_2 , phthalimidomethyl), 7.32 - 7.86 (m, 4H, quinazolinone), 7.94 - 8.03 (m, 4H, phthalimido-H).

Synthesis of Compounds 19a-c

The quinazolinone thiadiazole derivative **18a-c** was heated under reflux with formamide (0.01 mol each) for 3 h. The mixture was poured onto ice/water mixture with stirring leaving a white material to separate out and then begin to solidify forming gum. This material was washed with water, filtered and crystallized from ethanol as off-white needles of **19a-c**.

5-[2-Amino-4-oxoquinazolin-3(4H)-yl]-2-phenylthiadiazole **19a.** Yield 73 %, m.p. 243-245 °C. Anal. for $C_{18}H_{14}N_4O_2S$ (m.w. 350); Found: C, 61.76; H, 4.04; N, 16.02; S, 9.17; Calcd: C, 61.71; H, 4.00; N, 16.00; S, 9.14; IR υ (cm⁻¹) 1669 (C=O), 1531 (C=N); 3330 (NH); 3444 (CH); MS: m/z (int. %) [M+H]⁺ 350 (72.3); ¹H-NMR (DMSO-d₆) δ 2.11 (s, 2H, NH₂), 7.28-7.77 (m, 4H; quinazolinone), 7.41-7.93 (m, 5H; ph-H).

5-[2-Amino-4-oxoquinazolin-3(4H)-yl]-2-cinnamylthiadiazole **19b.** Yield 78 %, m.p. 262-263 °C. Anal. for $C_{20}H_{16}N_4O_2S$ (m.w. 376); Found: C, 63.87; H, 4.27; N, 14.91; S, 8.53; Calcd: C, 63.83; H, 4.26; N, 14.89; S, 8.51; IR v (cm⁻¹) 1670 (C=O), 1529 (C=N); 3392 (NH); 3433 (CH); MS: m/z (int. %) [M+H]⁺ 376 (78.3); ¹H-NMR (DMSO-d₆) δ 2.04 (s, NH, NH₂), 7.20, 7.47 (2d, 2H, J = 15.8 Hz, olefinic-H), 7.34-7.44 (m, 5H, Ph-H), 7.30-7.77 (m, 4 H, quinazolinone).

 $2-\{[5-(2-Amino-4-oxoquinazolin-3(4H)-yl)-1,3,4-thiadiazol-2-yl]\ methyl\}-1H-isoindole-1,3(2H)-dione$ **19c.** Yield 68 %, m.p. 272-273 °C. Anal. for $C_{19}H_{12}N_6O_3S$ (m.w. 404); Found: C, 56.49; H, 2.99; N, 20.83; S, 7.95; Calcd: C, 56.44; H, 2.97; N, 20.79; S, 7.92; IR υ (cm⁻¹) 1671, 1730, 1790 (3xC=O), 1528 (C=N); 3389 (NH); 3443 (CH); MS: m/z (int. %) [M+H]⁺ 404 (78.3); ¹H-NMR (DMSO-d₆) δ 2.00 (s, 2H, NH₂), 7.29-8.19 (m, 4H; ArH), 7.30-7.77 (m, 4 H, quinazolinone) .

Synthesis of Compounds 20a-c

Compound 19a-c (0.01 mol) was dissolved in 50 mL of dry toluene and cooled to 15 °C. To this solution was added drop wise an equimolar amount of chloroacetyl chloride with frequent stirring. The temperature of the reaction was brought slowly to room temperature an then the solution was heated under reflux for 4h. The excess toluene was distilled off and the resultant precipitate was filtered, washed repeatedly with dry toluene, dried and crystallized from aqueous dioxane affording compounds 20a-c.

2-Chloro-N-[3-(5-phenyl-1,3,4-thiadiazol-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]acetamide **20a.** White crystals from dioxane; m.p. 163-164 °C, yield 77 %. Anal. For $C_{18}H_{12}ClN_5O_2S$ (m.w. 397.5); Found: C, 54.38; H, 3.05; Cl, 8.96; N, 17.66; S, 8.08; Calcd: C, 54.34; H, 3.02; Cl, 8.93; N, 17.61; S, 8.05; IR v (cm⁻¹) 3230 (N-H), 3023 (Ar-H), 2995 (CH₂), 1668, 1699 (CO), 763 (CCl); MS: m/z (int. %) [M+H]⁺ 397.5



(68.4); ${}^{1}\text{H-NMR}$ (DMSO-d₆) δ 4.41 (s, 2H, $CH_{2}\text{Cl}$), 8.11 (s, 1H, NH), 7.38-7.93 (m, 4H, Ph-H) 7.21-8.19 (m, 4H, quinazolinone).

2-Chloro-N-(4-oxo-3-{5-[(E)-2-phenylethenyl]-1,3,4-thiadiazol-2-yl}-3,4-dihydroquinazolin-2-yl)acetamide **20b.** White crystals from dioxane; m.p. 171-173 °C, yield 81 %. Anal. For $C_{20}H_{14}Cl\ N_5O_2S$ (m.w. 423.5); Found: C, 56.71; H, 3.33; Cl, 8.40; N, 16.55; S, 7.58; Calcd: C, 56.67; H, 3.31; Cl, 8.38; N, 16.53; S, 7.56; IR ν (cm⁻¹) 3205 (N-H), 3010 (Ar-H), 2935 (CH₂), 1666, 1694, (CO), 775 (CCl); MS: m/z (int. %) [M+H]⁺ 423.5 (73.4); ¹H-NMR (DMSO-d₆) δ 4.41 (s, 2H, CH_2Cl), 8.00 (s, 1H, NH), 7.20, 7.47 (2 d, 2 H, olefin-H), 7.28-7.45 (m, 4H, cinnamyl moiety), 7.27-8.14 (m, 4H, quinazolinone).

2-Chloro-N-(3-{5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-1,3,4-thiadiazol-2-yl}-4-oxo-3,4-dihydroquinazolin-2-yl)acetamide **20c.** White crystals from dioxane; m.p. 179-181 °C, yield 73 %. Anal. for $C_{21}H_{13}ClN_6O_4S$ (m.w. 480.5); Found: C, 52.48; H, 2.74; Cl, 7.43; N, 14.57; S, 6.71; Calcd: C, 52.44; H, 2.71; Cl, 7.39; N, 14.48; S, 6.66; IR υ (cm⁻¹) 3205 (N-H), 3010 (Ar-H), 2935 (CH₂), 1666, 1694, 1776 (CO), 775 (CCl); MS: m/z (int. %) [M+H]⁺ 480.5 (73.4); ¹H-NMR (DMSO-d₆) δ 4.60 (s, 2H, CH_2Cl), 8.00 (s, 1H, NH), 7.25-7.85 (m, 4H, quinazolinone), 7.96-8.03 (m, 4H, phthalimido moiety).

2-Chloro-N-(2-ethoxy-4-oxoquinazolin-3(4H)-yl)acetamide **21.** Compound **3** (0.01 mol) was dissolved in 50 mL of dry toluene and cooled to 15 °C. To this solution was added drop wise an equimolar amount of chloroacetyl chloride with frequent stirring. The temperature of the reaction was brought slowly to room temperature and then the solution was heated under reflux for 4 h. The excess toluene was distilled off and the resultant precipitate was filtered, washed repeatedly with dry toluene, dried and then crystallized from aqueous dioxane as white crystals of compound **21**, m.p. 149-151 °C, yield 73 %. Anal. for $C_{12}H_{12}Cl N_3O_3$ (m.w. 281.5); Found: C, 51.15; H, 4.26; N, 14.92; Cl, 12.61; Calcd: C, 51.22; H, 4.29; N, 14.99; Cl, 12.66; IR v (cm⁻¹) 3205 (N-H), 3010 (ArC-H), 2935 (CH₂), 1666, 1694 (CO), 1568, 1328 (CN), 775 (CCl); MS: m/z (int. %) [M+H]⁺ 281 (73.4); ¹H-NMR (DMSO-d₆) δ 1.15 (t, 3H; OCH₂CH₃), 4.31 (s, 2H, CH₂Cl), 4.43 (q, 2H; OCH₂CH₃), 8.0 (s, 1H, NH), 7.28-8.20 (m, 4H, ArH).

3-Chloroacetyl-2-ethoxyquinazolin-4-one **22.** Compound **2** (0.01 mol) was refluxed with chloroacetyl chloride (0.01 mol) in 50 mL of dry pyridine for 4 h. The excess solvent was distilled off and the solution was left to cool and then poured onto ice with frequent stirring till a crude product was obtained. The latter was filtered off, thoroughly washed with cold water, dried and crystallized from ethanol affording brownish white crystals of derivative **8**; m.p. 152-153 °C; yield 85 %. Anal. for $C_{12}H_{11}N_2O_3Cl$ (m.w. 266.5); Found: C, 54.52; H, 5.69; N, 7.92; Cl, 13.32; Calcd: C, 54.54; H, 5.68; N, 7.95; Cl, 13.28; IR v (cm⁻¹) 1668, 1717 (2 C=O), 2823 (CH); MS: m/z (int. %) $[M+H]^+$ 266.5 (77.3); 1H -NMR (DMSO-d₆) δ 1.2 (t, 3H, -OCH₂CH₃, J = 7.4 Hz), 4.36 (q, 2H; -OCH₂CH₃, J = 7.4 Hz), 4.29 (d, 2H, CH_2 Cl), 7.45-8.20 (m, 4H, ArH).

Acknowledgment

Thanks to the Chemistry Department of Ain-Shams University for assistance to carry out the pilot project.

References

Mathew, B.P.; Kumar, A; Sharma, S; Shukla, P.K.; Nath, M. An eco-friendly synthesis and antimicrobial activities of dihydro-2*H*-benzo- and naphtho-1,3-oxazine derivatives. *Eur. J. Med. Chem.* **2010**, *45*, 1502-1507.

Pritchard, K.M.; Rawi, J.A.; Bradley, C.; Synthesis, identification and antiplatelet evaluation of 2-morpholino substituted benzoxazines. *Eur. J. Med. Chem.* **2007**, *42*, 1200-1210.



Pei-Wen Hsieh, Tsong-Long Hwang, Chin-Chung Wu, Fang-Rong Chang, Tsai-Wei Wang; Yang-Chang Wu. The evaluation of 2,8-disubstituted benzoxazinone derivatives as anti-inflammatory and anti-platelet aggregation agents. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2786–2789.

Ward, E; Johnson, N; Lovell, J.P.; Smith, W.; Thewlis, K.M.; Vong, A.K.; Natson, M.J. Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5214-5217.

Deswal, S.; Roy, N. Quantitative structure activity relationship of benzoxazinone derivatives as neuropeptide Y Y5 receptor antagonists. *Eur. J. Med. Chem.* **2006**, *41*, 552-557.

Ohno, M.; Tanaka, Y.; Miyamoto, M.; Takeda, T.; Hoshi, K.; Yamada, M. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A_2 receptor antagonists and prostacyclin receptor agonists. *Bioorg. Med. Chem. Lett.* **2006**, *14*, 2005-2021.

Kern, J.C.; Terefenko, E.A.; Fensome, A.; Unwalla, R.; Wrobel, J.; Zhou, Y.; Cohen, J.; Winneker, R.; Zhang, Z.; Zhang, P. SAR studies of 6-(arylamino)-4,4-disubstituted-1-methyl-1,4-dihydro-benzo[*d*] [1,3]oxazin-2-ones as progesterone receptor antagonists. *Bioorg, Med. Chem. Lett.* **2007**, *17*, 189-192.

Powell, N.A.; Ciske, F.L.; Cai, C.; Holsworth, D.D.; Huis, C.A.; Jalaie, M.; Day, J.; Mastronrdi, M.; McConnell, P.; Mochalkin, I.; *et al.* Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule rennin inhibitors. *Bioorg. Med. Chem.* **2007**, *15*, 5912-5949.

Bromidge, S.M.; Bertani, B.; Borriello, M.; Bozzoli, A.; Faedo, S.; Gianotti, M.;Gordon, L.J.;Hill, M.; Zucchelli, V.; Watson, J.M.; Zonzini, L.; 8-[2-(4-Aryl-1-piperazinyl)ethyl]-2*H*-1,4-benzoxazin-3(4*H*)-ones: dual-acting 5-HT₁ receptor antagonists and serotonin reuptake inhibitors-Part II. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2338-2342.

Shakil, N.A.; Pandey, A.; Singh, M.K.; Kumar, J.; Awasthi, S.K.; Srivastava, C.; Singh, M.K.; Pandey, R.P. Synthesis and bioefficacy evaluation of new 3-substituted-3,4-dihydro-1,3-benzoxazines. *J. Environ. Sci. Health B.* **2010**, *45*, 108-115.

Wang, L.; Ankati, H.; Akubathini, S.K.; Balderamos, M.; Storey, C.A.; Patel, A.V.; Price, V.; Kretzschmar, D.; Biehl, E.R. D'Mello, S.R. Identification of novel 1,4-benzoxazine compounds that are protective in tissue culture and *in vivo* models of neurodegeneration. *J. Neurosci Res.* **2010**, *88*, 1970-1984.

Dong, Z.; Cheng, Y.; Zhao, J.; Su, L.; Zhao, B.; Zhang, Y.; Zhang, S.; Miao, J. Discovery of a benzoxazine derivative promoting angiogenesis *in vitro* and *in vivo*. *J. Cell Physiol.* **2010**, 223, 202-208.

Bartroli, J.; Turmo, E.; Alguero, M.; Boncompte, E.; Vericat, M.L.; Coute, L.; Ramis, J.; Merlos, M.; Garcia-Rafanell, J.; Forn, J.; "New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3*H*)-quinazolinones," *J. Med. Chem.* **1998**, *41*, 1869–82.

Shiba, S.A.; El-Khamry, A.A.; Shaban, M.E.; Atia, K.S.; "ChemInform Abstract: Synthesis and Antimicrobial Activity of Some Bis-quinazoline Derivatives," *Pharmazie*, **1997**, *52*, 189-194.

Abdel-Hamid, S.G.; "Synthesis of some New Heterocyclic Systems Bearing 2-Phenyl-6-iodo-4-(3*H*)-quinazolinon-3-vl Moiety as Antibacterial Agents," *J. Ind. Chem. Soc.*, **1997**, 74, 613-618.

Barker, A.; "Preparation of 4-Anilinoquinazolines as Anticancer Agents," *J. Eur. Pat.* **1995**, 635498; *Chem. Abstr.* **1995**, 122, 214099.



Bekhit, A.A.; Khalil, M.A.; "A Non-steroidal Antiinflammatory Agents: Synthesis of Novel Benzo-pyrazolyl and Quinazolinyl Derivatives of 4(3*H*)-Quinazolinones," *Pharmazie*, **1998**, *53*, 539-543.

Gursoy, A.; Karali, N.; "Synthesis and Anticonvulsant Activity of New Acylthiosemicarbazides and Thiazolidones," *Farmaco*, **1995**, *50*, 857-866.

Nawrocka, W.; Zimecki, M.; "Syntheses of novel 3-amino-2(1*H*)-thioxo-4(3*H*)-quinazolinones and evaluation of their immunotropic activity. Part III," *Arch. Pharm.*, **1997**, *330*, 399-405.

Kurogi, Y.; Inoue, Y.; Tsutsumi, K.; Nakamura, S.; Nagao, K.; Yoshitsugu, H.; Tsuda, Y.; "Synthesis and hypolipidemic activities of novel 2-[4-[diethoxyphosphoryl)methyl]phenyl] quinazolines and 4(3*H*)-quinazolinones," *J. Med. Chem.* **1996**, *39*, 1433-7.

Hame E.; Lin C.M.; Plowman J.; Wang H.K.; Lee K.H. and Paull K. D.; "Antitumor 2,3-dihydro-2-(aryl)-4(1*H*)- quinazolinone derivatives :Interactions with tubulin," *Biochem. Pharmacol.*, **1996**, *51*, 53-59.

Terashima, K.; Shimamura, H.; Kawase, A.; Tanaka, Y.; Tanimura, T.; Kamisaki, T.; Ishizuka, Y. and Sato, M.; "Studies on Antiulcer Agents. IV. Antiulcer Effects of 2-Benzylthio-5,6,7,8-tetrahydro-4(3*H*)-quinazolinones and Related Compounds," *Chem. Pharm. Bull.* **1995**, *43*, 2021-2023.

Raffa, D.; Dailone, G; Maggio, B.; Sehillaci, D. and Plescia, F.; "Synthesis and Antiproliferative Activity of Novel 3-(Indazol-3-yl)-quinazolin-4(3*H*)-one and 3-(Indazol-3-yl-benzotriazin-4(3*H*)-one Derivatives," *Arch. Pharm.* **1999**, *332*, 317-320.

Baek, D.J.; Park, Y.K.; Heo, H.I.; Lee, M.H.; Yang, Z.Y.; Chio, M.H.; "Synthesis of 5-substituted quinazolinone derivatives and their inhibitory activity *in vitro*," *Bioorg. Med. Chem. Lett.* **1998**, 8, 3287-3290.

Griffin, R.J.; Srinivasan, S.; Bowman, K.; Calvert, A.H.; Curtin, N.J.; Newell, D.R.; Pemberton, L.C.; Golding, BT; "Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)," *J. Med. Chem.* **1998**, *41*, 5247-5256.

Jhone, S.; In *Progress in Drug Research*. In: "Search for Pharmaceutically interesting Quinazoline Derivatives: Efforts and Results (1969-1980)," ed. Jucker, E., Ed.; Birkauser Verlag: Basel; 26 (1982) 259-341.

Brown, D.J.; The Chemistry of Heterocyclic Compounds, J. Wiley & Sons: New York, 1996.

Armarego, W; Fused Pyrimidines: Part I - Quinazolines, Interscience Publishers: New York-London - Sydney, 1967.

Nakagami, K.; Yokoi, S.; Nishimura, K.; Nagai, S.; Honda, T.; Oda, K.; Kobayashi, R.; Kojima, M.; US Patent 4323680, 1982.

Haley, G.J.; US Patent 5373011, 1994.

Palanki, M.; Suto, M.; US Patent 5939421, 1999.

Myers, M.R.; Spada, A; Maguire, M; Persons, P; Zilberstein, A; Hsu, C-Y-J; Johnson, S E; US Patent 5714493, 1998.

Baker, A.J.; US Patent 5932574, 1999.



Baker, A.J.; US Patent 5942514, 1999.

Nauta, W.T.; US Patent 3980650, 1976.

Mizogami, S.; Hiranuma, H.; Sekiya, T.; Hanazuka, M.; US Patent 4607034, 1986.

Berger, M.; Albrecht, B.; Breces, A.; Neruda, W. and Woisetschläger, M.; "*S*(+)-4-(1-Phenyl- ethylamino) quinazolines as Inhibitors of Human Immunoglobuline E Synthesis: Potency is dictated by stereochemistry and atomic point charges at N-1," J. Med. Chem. 44 (2001) 3031.

Bridges, A.J.; "Chemical inhibitors of protein kinases," Chem. Rev. 101(2001) 2541.

Katritzky, A.R.; Rees, C.W.; Comprehensive Heterocyclic Chemistry II, Eds; Pergamon Press: Oxford, 1996.

Katritzky, A.R.; Pozharski, A.F.; *Handbook of Heterocyclic Chemistry*, 2nd Edn., Pergamon: New York, 2000.

Gao, Y.L.; Zhao, G.L.; Liu, W.; Shao, H.; Wang, Y.L.; Xu, W.R.; Tang, L.D. and Wang, J. W.; "Design, synthesis and *in vivo* hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors," Ind. J. of Chem., **2010**, *49B*, 1499-1508.

Krantz, A.; Spencer, R.W.; Tam, T.F.; Liak, T.J.; Copp, L.J.; Thomas, E.M. and Rafferty, S.P.; "Design and synthesis of 4*H*-3,1-benzoxazin-4-ones as potent alternate substrate inhibitors of human leukocyte elastase," J. Med. Chem. 33 (1990) 464-479.

This academic article was published by The International Institute for Science, Technology and Education (IISTE). The IISTE is a pioneer in the Open Access Publishing service based in the U.S. and Europe. The aim of the institute is Accelerating Global Knowledge Sharing.

More information about the publisher can be found in the IISTE's homepage: http://www.iiste.org

The IISTE is currently hosting more than 30 peer-reviewed academic journals and collaborating with academic institutions around the world. **Prospective authors of IISTE journals can find the submission instruction on the following page:** http://www.iiste.org/Journals/

The IISTE editorial team promises to the review and publish all the qualified submissions in a fast manner. All the journals articles are available online to the readers all over the world without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. Printed version of the journals is also available upon request of readers and authors.

IISTE Knowledge Sharing Partners

EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open Archives Harvester, Bielefeld Academic Search Engine, Elektronische Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digtial Library, NewJour, Google Scholar

























